surmount-1 tirzepatide weight loss percent nejm 2022

surmount-1 tirzepatide weight loss percent nejm 2022 Presented at ECO 2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body and waist circumference. Full trial Surmount Press Briefing #ADA2022

Name: surmount-1 tirzepatide weight loss percent nejm 2022 Presented at ECO 2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body and waist circumference. Full trial Surmount Press Briefing #ADA2022
Brand: museeartisanaletruralclion.fr
SKU: 72124344020
Price: 22.94 USD
Availability: InStock
Rating: 4.18 (25 reviews)

SKU: 72124344020

4.2

USD22.94 USD50.94

Pay in 4 interest-free payments of $5.74 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

Description

The XGBoost algorithm per se is not intended to be used in routine clinical work but was employed here to identify continuous baseline variables that predict the change in HbA1c and which can easily be evaluated by clinicians to provide a better overall assessment of the likely treatment response (such that for example a patient with high BMI or low insulin secretion will likely have a more pronounced response to a particular drug) in conjunction with other clinical data and the general patient context